AOD aka Advanced Obesity Drug., Fat Loss Peptide AOD 9604 consists of the get along 15 amino acids of the human wealth hormone molecule. The considerable thing close but no cigar AOD 9604 is it has no doom on accomplishment or insulin resistance. With an fine safety sketch of minimal side chattels personal, AOD 9604 has been proven more effective than consequently occuring Growth Hormone at fresh the collapse of fat. Studies have proven its efficiency to reduce biggest slice of the cake full, by way of explanation in the abdominal area.

When you buy peptides online through Peptide Clinics you can be ensured of our commitment to your success. Peptide Clinics specialises in supplying premium peptide supplements, incorporated into custom treatment programs to assist you in meeting your health and fitness goals. All new client questionnaires are screened by one of our highly trained and experienced medical doctors. All initial and follow-up blood tests are also screened by our doctors, who use this information to recommend the peptide best suited for you, with its dose and frequency. Programs are customised on a per client basis dependent on your goals and blood test results, which are regularly reviewed and modified to ensure optimal peptide performance.
Increasing HGH release levels in your body naturally. It sounds too good to be true, but what if you could achieve just that by using a supplement? Using Ipamorelin alongside your exercise and diet regimen is going to help you achieve said goal. No two users are alike. For athletes or those who workout religiously, you might experience greater results than an individual who is overweight and just getting back into the gym after 10 years. So, take it with a grain of salt when detailing the results below. Dosage, your body composition, and other factors will play a role in the results you can expect to see when you incorporate Ipamorelin.
Advanced Obesity Drug 9604 (AOD9604), targets fat metabolism directly by enhancing the breakdown of stored fats and inhibiting the synthesis of new fats. It is a peptide drug derived from the fat-reducing activity of human growth hormone (hGH). hGH has been shown to cause fat reduction, but is not suitable as an anti-obesity drug as it also causes an increase in muscle, organ and bone mass as well as causing diabetes to develop. The effectiveness of hGH declines in older people, correlating with the tendency to put on weight as one gets older. In support of this, the clinical trials so far have shown a greater effect of AOD9604 in the older population.
I can't believe we as Aussies are the 1st to point the finger of other countries on drug cheats, as soon as its in our own backyard and one of our afl footy teams, we seem to downplay the seriousness of drugs in sport, its crazy, and to think they didnt know what was being injected, doh. my favorite is the Shane Warne Diuretics that his mum gave him, lol, 12 month ban, Essendon minimum 2 year ban.....has to be.

EPO: Erythropoietin (EPO) is a naturally occurring hormone found in the blood, but media usually refer to the artificial peptide (recombinant EPO). EPO stimulates production of red blood cells to improve oxygen transfer and boost endurance or recovery from anaerobic exercise. EPO is also believed to increase the risk of adverse health effects, but this has mainly been based on athletes’ anecdotal evidence and clinical studies in non-sports patients with other medical conditions. While using recombinant EPO is prohibited both in and out of competition under WADA’s Prohibited List, “natural” boosting of EPO through high altitude training is allowed.
Ghrelin and GH secretagogues, including GH-releasing peptide (GHRP)-6, stimulate food intake and adiposity. Because insulin modulates the hypothalamic response to GH secretagogues and acts synergistically with ghrelin on lipogenesis in vitro, we analyzed whether insulin plays a role in the metabolic effects of GHRP-6 in vivo. Streptozotocin-induced diabetic rats received saline, GHRP-6, insulin, or insulin plus GHRP-6 once daily for 8 wk. Rats receiving saline suffered hyperglycemia, hyperphagia, polydipsia, and weight loss. Insulin, but not GHRP-6, improved these parameters (P < 0.001 for all), as well as the diabetes-induced increase in hypothalamic mRNA levels of neuropeptide Y and agouti-related peptide and decrease in proopiomelanocortin. Cocaine amphetamine-related transcript mRNA levels were also reduced in diabetic rats, with GHRP-6 inducing a further decrease (P < 0.03) and insulin an increase. Diabetic rats receiving insulin plus GHRP-6 gained more weight and had increased epididymal fat mass and serum leptin levels compared with all other groups (P < 0.001). In epididymal adipose tissue, diabetic rats injected with saline had smaller adipocytes (P < 0.001), decreased fatty acid synthase (FAS; P < 0.001), and glucose transporter-4 (P < 0.001) and increased hormone sensitive lipase (P < 0.001) and proliferator-activated receptor-gamma mRNA levels (P < 0.01). Insulin normalized these parameters to control values. GHRP-6 treatment increased FAS and glucose transporter-4 gene expression and potentiated insulin's effect on epididymal fat mass, adipocyte size (P < 0.001), FAS (P < 0.001), and glucose transporter-4 (P < 0.05). In conclusion, GHRP-6 and insulin exert an additive effect on weight gain and visceral fat mass accrual in diabetic rats, indicating that some of GHRP-6's metabolic effects depend on the insulin/glucose status.
Lean C57BL/6J and obese (ob/ob) mice aged 12 wk were used in this study. There were 18 mice in each group, and they were divided into three treatment groups [saline (n = 6); AOD (250μ g/kg·d; n = 6); hGH (1 mg/k·d; n = 6)]. The animals were housed in the Departmental Animal Facility at a constant temperature and humidity in a 12-h light, 12-h dark cycle. Animals were injected with a single intraperitoneal dose of saline, AOD9604, or hGH at 0800 h each day for 14 d using a 1-ml syringe and 23-gauge needle. The body weights of the animals were recorded every second day along with food intake.
I'm using 100mcg 6am-12pm-6pm(3xday) HGH Fragment 176-191 and the last shot around 6pm taking 100mcg of GHRP-6 from SouthernResearchCo, I gotta brag on their quality and value there's no others on the same level (IMO)! I dropped 10-15lbs as soon as I started too! NO catabolic or any adverse effects. Well, I did get head aches and super shits when I first began but by wk2 I notice nothing and feel so great! My tummy looks so much better too, my wifes all jealous as hell n gets mad saying she wont compliment it cuz I use drugs to attain leanness lol Fk it
Figure 1A shows the chronic effect of saline, AOD9604, and hGH in lean C57BL/6J mice on body weight and food intake. The hGH potently increased the body weight gain of these mice, reaching significance by d 8. There was an increase in body weight after AOD9604 only on the last day of treatment. In contrast, ob/ob mice (Fig. 1B) showed a profound decrease in body weight after both AOD9604 and hGH. Importantly, these effects were not attributed to changes in food intake in either the lean or the ob/ob mice (Fig. 1, C and D, respectively).
AOD has been shown to target abnormal fat stores, and to prevent fat from being stored in the cells. Studies have shown that it reduces the most stubborn fat regions (like abdominal fat). It also has other benefits including increasing muscle mass, increasing IGF-1 (insulin growth factor) in a positive way to metabolise fat, and increase the amount of energy burned for the same amount of activity.
At both visits, saline infusion was associated with a significant increase in left ventricular (LV) end‐diastolic volume (P=0.001 for saline effect), whereas LV end‐systolic volume was unchanged. Stroke volume and cardiac output increased in response to saline administration at both pre‐ and post‐bypass visits. The effect of saline infusion on cardiac function did not differ before and after surgery (saline×surgery interaction P values non‐significant).
Plasma Nt‐proANP levels were measured by ELISA (proANP 1‐98; Biomedica Medizinprodukte GmbH & Co KG, Austria). Plasma Nt‐proBNP levels were measured using an electrochemiluminescence immunoassay (Elecsys proBNP; Roche, Indianapolis, IN). Mature ANP was measured using an in‐house immunoassay at the Mayo Clinic (Rochester, MN; J. Burnett). Mature BNP was measured by immunoassay (Siemens, New York, NY). Intra‐assay coefficients of variation were <10% for all assays.

At Ageing Solutions, we believe in providing you the supplementation, medication, and support to help you stick to your health and fitness resolutions. Our team of highly experienced Physicians and Compounding Pharmacists as well as our Senior Scientist have developed our Medical Weight Loss Programs to provide you with the right medication and detailed food/nutrient programs to help you kick start your weight loss goals.


We found that osteoarthritic rabbits administered intra-articular AOD9604 injections had better outcomes with lesser morphological and histolopathological damage than was observed in the control group. AOD9604 is a disulphide-constrained peptide that comprises 15 amino acids from the C-terminal sequence of human GH and an additional N-terminal tyrosine residue: YLRIVQCRSVEGSCGF [15]. The exact mechanism underlying the action of GH in OA is unknown. Previous studies have shown that GH can act directly on the growth plate by stimulating local production of IGF-1 and by increasing cartilage metabolism [9,16] and chondrocyte proliferation [17]. Although AOD9604 is not a high-affinity agonist of the GH receptor and does not stimulate the proliferation of cells transfected with the GH receptor, it retains some functions of GH [11]. Initially, AOD9604 was investigated for the treatment of obesity in humans. In rodent models of obesity, AOD9604 showed a similar effect of weight loss as that observed with GH [11]. However, AOD9604 does not induce diabetes and does not stimulate the production of IGF-1 [10].
Obesity affects as many as one in five adults in developed countries. Metabolic estimates that the potential worldwide market for effective obesity drugs is as much as $20 billion, far more than the current market of $1.5 billion. This is partly due to the potential need for chronically obese people to take obesity drugs such as AOD9604 and also because patients are put off using currently available drugs because of their marginal efficacy or side-effects.
There are several limitations of our study. Given the nature of our physiologic protocols, which required two large volume saline infusions in obese patients before and after surgery, our sample size was modest. Nonetheless, we were able to elicit significant relationships of all four natriuretic peptides (ANP, Nt‐proANP, BNP, and Nt‐proBNP) across a variety of salt conditions before and after surgical weight loss. Our study population consisted of primarily females. We do not believe from prior epidemiologic studies looking at resting natriuretic peptide levels in obese individuals12 that having more men in our cohort would have modified our findings. Prior epidemiologic studies do not suggest that gender modifies the association between obesity and natriuretic peptide concentrations. We did not examine short‐term changes in the natriuretic peptide system, as a physiologic assessment immediately after surgery would have been impractical and potentially confounded by post‐operative shifts in volume or nutrition. We also focused on surgical weight loss because weight loss with non‐surgical treatments is less consistent. Thus, we cannot exclude any surgery‐specific effects. Because the saline infusion was indexed to BSA, less saline was given at the post‐weight loss visit. This could have created a “conservative” bias, eg, toward observing a smaller natriuretic peptide response after surgery. Indexing was performed to ensure that the amount of saline relative to plasma volume was relatively constant. Lastly, we did not perform a complete assessment of the renin‐angiotensin‐aldosterone system and the sympathetic nervous system, all of which could also be primarily affected resulting in the observed responses of the natriuretic peptide system after weight loss and/or saline loading.

Growth Hormone (GH) and IGF-1 are naturally occurring hormones in the human body responsible for many enviable aesthetic traits such as muscle mass, leanness and a firm/even skin tone. As people age, levels of growth hormone rapidly decline and this is one of the main reasons humans put on weight, lose muscle mass and develop sagging/uneven skin. It's no surprise then that synthetic Human Growth Hormone is a sought after product for anti-aging by persons looking to remain youthful, bodybuilders looking to put on muscle mass and people in general who are looking to "tone up" or lose stubborn belly fat.


From the standpoint of protein synthesis and muscle repair, IGF-1 injections have also been shown to enhance the anticatabolic effects of insulin and to increase the protein synthesis normally induced by growth hormone. This is because, like insulin, IGF-1 encourages amino acid uptake into muscle cells, stimulates peripheral tissue uptake of glucose (which lowers blood glucose levels), and suppresses liver glucose production. That last fact is important and is actually why IGF-1 is even being considered as a diabetes-prevention drug. Insulin resistance can cause the liver to produce excess glucose, which then causes even more insulin insensitivity and can eventually result in type II diabetes, and IGF-1 can decrease the need for this type excessive insulin release.
A total number of 207 AEs were reported by 36/36 subjects. All but one was of mild to moderate intensity (placebo-treated subject, soft tissue injury to left shoulder, unrelated to study treatment). No SAE occurred during the 7-day treatment and the 7-day follow-up time. The rate as well as the AE profile was comparable in the 9 mg, 27 mg AOD9604 and the placebo group. There was no observable trend between treatment groups with respect to the incidence of certain AEs, however subjects who received 54 mg AOD9604 experienced a greater number of headaches, diarrhea and flatulence.

Mean gross morphological and histopathological scores in Group 1 were significantly higher than those in Groups 2, 3, and 4 (p<0.05). Mean gross morphological and histopathological scores in Group 4 were significantly lower than those in Groups 2 and 3 (p<0.05). However, there are no differences between the mean gross morphological and histopathological scores of Groups 2 and 3 (Figures 4 and 5).


Buy Peptides online from Australia’s most respected supplier of clinical grade peptides. Peptides Online produces only the highest quality peptide products. We are fully licensed and registered with our offices located in Australia. Specializing in the production of medically prescribed, pharmaceutical grade peptides, Peptide Online guarantees optimal purity and potency of their peptide supplements.
×